Form 8-K - Current report:
SEC Accession No. 0000950170-22-004229
Filing Date
2022-03-21
Accepted
2022-03-21 16:11:45
Documents
14
Period of Report
2022-03-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tern-20220321.htm   iXBRL 8-K 53204
2 EX-99.1 tern-ex99_1.htm EX-99.1 22337
3 GRAPHIC img52906712_0.jpg GRAPHIC 6619
  Complete submission text file 0000950170-22-004229.txt   215299

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tern-20220321_lab.xml EX-101.LAB 14668
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tern-20220321_pre.xml EX-101.PRE 10787
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tern-20220321.xsd EX-101.SCH 2504
8 EXTRACTED XBRL INSTANCE DOCUMENT tern-20220321_htm.xml XML 5119
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 22755821
SIC: 2834 Pharmaceutical Preparations